Devices & Diagnostics

Optum’s effectiveness mash-up: Combining United’s 40M claims + 7M hospital records to test devices

SharedClarity has created an alliance of long-time healthcare frenemies (payers and providers) to test effectiveness of heart and orthopedic medical devices with the aim of lowering costs, reducing readmissions, allowing members to negotiate device pricing and getting patients effective implantable devices. For the study, United Healthcare will join forces with Baylor Healthcare System in Dallas, Dignity Health in […]

SharedClarity has created an alliance of long-time healthcare frenemies (payers and providers) to test effectiveness of heart and orthopedic medical devices with the aim of lowering costs, reducing readmissions, allowing members to negotiate device pricing and getting patients effective implantable devices. For the study, United Healthcare will join forces with Baylor Healthcare System in Dallas, Dignity Health in San Francisco and Advocate Healthcare in Illinois.

Between the 40,000,000 United claims and the 7,000,000-plus patients the healthcare systems represent, SharedClarity President Mark West said the study will provide an independent analysis of which devices are the most effective. (Optum Labs will oversee the research.)

“What’s really unique about SharedClarity is the data that we can pull together,” West said. “It’s data that were not aware that anyone else has been able to pull together and analyze.”

The first 30 types of devices slated for testing are centered around heart and orthopedic implantables. They’re all “high clinical impact” products that directly contribute to patient well-being, West said.

Eventually, this information will allow members to negotiate pricing with medical device companies (and the logical leap: this will probably affect which devices payers are willing to cover, too).

The theory is it should also cut readmissions and provide better outcomes for patients–both of which would take cost out of the system.

The tests, which are led by member physicians, are about four months in on clinical evaluations of the first three devices: peripheral stents, bare metal stents and drug-eluding stents. While West couldn’t comment on the findings of these studies, he said they should be finished by the end of the year.

Sponsored Post

Physician Targeting Using Real-time Data: How PurpleLab’s Alerts Can Help

By leveraging real-time data that offers unprecedented insights into physician behavior and patient outcomes, companies can gain a competitive advantage with prescribers. PurpleLab®, a healthcare analytics platform with one of the largest medical and pharmaceutical claims databases in the United States, recently announced the launch of Alerts which translates complex information into actionable insights, empowering companies to identify the right physicians to target, determine the most effective marketing strategies and ultimately improve patient care.

For now, the company plans to share the information only with members and anticipates adding more health system members soon.

Bottom line: As healthcare moves toward wellness and effectiveness and major players (even in the conservative device industry) begin to expand business to “healthcare service,” this kind of union will become more and more common. In the near future of healthcare, we can plan to see plenty of these formerly unlikely power-driven partnerships arise to save providers, payers and (lest we forget) patients money.